RxDoctor Payments Data

Linden Schild, MD

Psychiatry · Chester, NYNPI 1831156710

Payments from drug & device makers

$58,362in general payments, 2019–2025

Across 354 payments — averaging $164.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$46K
  • Supernus Pharmaceuticals, Inc.$11K
  • Sunovion Pharmaceuticals Inc.$602
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$207
  • Takeda Pharmaceuticals U.S.A., Inc.$79
  • Corium, LLC$74
  • plus $153 from 7 others

What the payments were for

  • Speaking & faculty fees$51,30088%
  • Travel & lodging$2,3234%
  • Food & beverage$4,6298%
  • Education$1100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$58,362 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$45,829
Medicare patients
100
Services billed
671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl176$320,091
VyvanseLisdexamfetamine Dimesylate104$41,765
Lurasidone Hcl42$30,878
RexultiBrexpiprazole18$28,908
CaplytaLumateperone Tosylate12$19,618
Aripiprazole166$16,358
AzstarysSerdexmethylphen/Dexmethylphen25$10,039
Methylphenidate ErMethylphenidate Hcl32$6,865
Bupropion XlBupropion Hcl217$5,266
Atomoxetine Hcl29$4,946
Duloxetine Hcl167$4,527
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine128$4,283
Clonazepam369$4,209
Alprazolam378$3,099
Buspirone Hcl160$2,951

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$46,017$320,091176 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$79$41,765104 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$207$19,61812 claims
Corium, LLCAzstarys$74$10,03925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Chester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →